A CLINICAL TRIAL TO ASSESS THE COMBINED EFFECT OF PRATIMARSHA NASYA WITH KSHIRABALA 101 AND INTERNAL ADMINISTRATION OF HINGUVACADI CHOORNA IN THE MANAGEMENT OF PREMENSTRUAL SYNDROME(PMS)

AN OPEN LABEL SINGLE ARM CLINICALTRIAL TO ASSESS THE COMBINED EFFECT OF PRATIMARSHA NASYA WITH KSHEERABALA 101 AVARTI AND ORAL ADMINISTRATION OF HINGUVACHADI CHURNA IN THE MANAGEMENT OF PREMENSTRUAL SYNDROME(PMS)

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020168

Enrollment

Registered

2019-07-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients with premenstrual problems Health Condition 2: F59- Unspecified behavioral syndromes associated with physiological disturbances and physical factors

Interventions

Intervention1: Vaiswanara choornam sukumara ghrtam Dhanvantara taila gandharvahastadi erandam triphala kashaya Hinguvachadi choornam Ksheera bala 101 : Vaisvanara curnam (12gms) for days before food.

Eligibility

Inclusion criteria

Inclusion criteria: Age group 18 to 40 Both married and uynmarried females PMS scale score <40

Exclusion criteria

Exclusion criteria: Patients who are under HRT who are pregnant Patient under prolonged medication for hypertension ,diabetes mellitus,hypothyrodism Patients under anti depressents and other psychiatric treatments

Design outcomes

Primary

Measure	Time frame
we are observing the reduction in physiological,behavioural,psychological signs and symptoms at baseline visit,and next three consecutive menstrual cycle with Premenstrual syndrome scale.Timepoint: The PMS scale score greater than 40 was selected for the study and categorised for mild,moderate and severe pms.It is given at baseline and for next three consecutive menstrual cycle for the total study duration of 18 months.	—

Measure

Time frame

we are observing the reduction in physiological,behavioural,psychological signs and symptoms at baseline visit,and next three consecutive menstrual cycle with Premenstrual syndrome scale.Timepoint: The PMS scale score greater than 40 was selected for the study and categorised for mild,moderate and severe pms.It is given at baseline and for next three consecutive menstrual cycle for the total study duration of 18 months.

—

Secondary

Measure	Time frame
we are observing for presence of any headaches after treamentTimepoint: 7 days	—

Countries

India

Contacts

Public ContactDr ChippyPR

HOD and Professor, Department Of Striroga and Prasuti tantra

drhemavathi.sk@gmail.com9446962291

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026